Sinocare Inc., established in 2002 and headquartered in Changsha, China, is a leading high-tech enterprise specializing in biosensing technology and chronic disease management. As the first listed blood glucose meter manufacturer in China (SZSE: 300298), the company has grown into the world's fifth-largest blood glucose meter manufacturer and operates the largest production base for blood glucose monitoring systems in Asia, spanning 66,000 square meters. With a global workforce of over 3,500 employees and nine R&D and production sites, Sinocare serves more than 25 million users across 187 countries and regions.
The company provides a comprehensive portfolio of rapid diagnostic testing products and Point-of-Care Testing (POCT) solutions. Core product lines include blood glucose monitoring systems (BGMS), continuous glucose monitoring (CGM) systems, uric acid monitors, blood pressure monitors, and multiparameter testing devices for blood lipids, ketone, and HbA1c. Sinocare also offers professional medical services and digital health management solutions, including the AGEscan diabetes risk screening system and integrated hospital-grade diagnostic equipment.
Operating as both a manufacturer and trading company, Sinocare provides extensive OEM and ODM services to international partners. The company maintains rigorous quality standards, holding certifications such as ISO 9001, ISO 13485, CE, GMP, MDSAP, and IVDR. Following the strategic acquisitions of Trividia Health and PTS Diagnostics, Sinocare has solidified its position as a global leader in the biotechnology and medical device industries, bridging the gap between prevention and chronic disease management through its innovative 'A+C' Diabetes Ecosystem.